Vallés Jordi, Mariscal Dolors
Centre de Crítics, Hospital de Sabadell, Institut Universitari Parc Taulí, Sabadell, Barcelona, España.
Enferm Infecc Microbiol Clin. 2005 Dec;23 Suppl 3:30-6. doi: 10.1157/13091218.
Pseudomonas aeruginosa is one of the leading causes of Gram-negative nosocomial pneumonia. It is the most common cause of ventilator-associated pneumonia and carries the highest mortality among hospital-acquired infections. P. aeruginosa produces a large number of toxins and surface components that make it especially virulent compared with other microorganisms. These include pili, flagella, membrane bound lipopolysaccharide, and secreted products such as exotoxins A, S and U, elastase, alkaline protease, cytotoxins and phospholipases. The most common mechanism of infection in mechanically ventilated patients is through aspiration of upper respiratory tract secretions previously colonized in the process of routine nursing care or via contaminated hands of hospital personnel. Intravenous therapy with an antipseudomonal regimen should be started immediately when P. aeruginosa pneumonia is suspected or confirmed. Empiric therapy with drugs active against P. aeruginosa should be started, especially in patients who have received previous antibiotics or present late-onset pneumonia.
铜绿假单胞菌是革兰氏阴性医院获得性肺炎的主要病因之一。它是呼吸机相关性肺炎最常见的病因,在医院获得性感染中死亡率最高。与其他微生物相比,铜绿假单胞菌产生大量毒素和表面成分,使其具有特别强的毒性。这些包括菌毛、鞭毛、膜结合脂多糖以及分泌产物,如外毒素A、S和U、弹性蛋白酶、碱性蛋白酶、细胞毒素和磷脂酶。机械通气患者最常见的感染机制是通过吸入在常规护理过程中预先定植的上呼吸道分泌物,或通过医院工作人员受污染的手。当怀疑或确诊为铜绿假单胞菌肺炎时,应立即开始使用抗假单胞菌方案进行静脉治疗。应开始使用对铜绿假单胞菌有活性的药物进行经验性治疗,特别是在之前接受过抗生素治疗或出现迟发性肺炎的患者中。